RX 0201

Drug Profile

RX 0201

Alternative Names: Archexin; RX-0201; RX-0201 Nano; RX-0201-N; RX-0201-nanoliposomal

Latest Information Update: 21 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rexahn Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Gastric cancer; Ovarian cancer; Renal cell carcinoma; Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pancreatic cancer; Renal cell carcinoma
  • Preclinical Ovarian cancer

Most Recent Events

  • 21 May 2018 RX 0201 is still in preclinical trials for Ovarian cancer (Combination therapy, Second-line therapy or greater) in USA
  • 12 Mar 2018 Rexahn Pharmaceuticals and Zhejiang Haichang Biotechnology plan a phase IIa trial for liver cancer
  • 08 Feb 2018 Rexahn Pharmaceuticals terminates a phase II trial in Renal cell carcinoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA as the company planned to discontinue the internally funded programs of RX 0201 in Renal Cell Carcinoma (IV) (NCT02089334)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top